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INTRODUCTION 
Preeclampsia complicating pregnancy is a common multisystem 
disorder characterized by blood pressure ≥ 140/90 mmHg after 20 weeks 
gestation with proteinuria ≥300mg/24 hours or ≥I +dipstick.  
Preeclampsia forms one of the deadly triad along with haemorrhage and 
infection that contributes greatly to  maternal morbidity and mortality. It 
complicates 5-8% of the pregnancy. (ACOG 2002)1 
Management of mild preeclampsia remote from term, the 
traditional approach adopted has been balancing the maternal and fetal 
outcome. Conversely management of severe preeclampsia remote from 
term has been delivering without delay regardless of fetal outcome. 
With improved methods of monitoring and neonatal care 
facilities, several investigators has began to challenge the traditional 
view that women with severe preeclampsia need to be delivered 
expectantly. 
Recent trend advocates expectant management in a selected group 
of women with preeclampsia remote from term with the aim of 
improving fetal outcome without compromising maternal safety. 
Gestational age at delivery, rather than the severity of  maternal disease, 
is the primary determinant of perinatal outcome. 
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REVIEW OF LITERATURE 
MINIMUM CRITERIA FOR DEFINING PREECLAMPSIA  
(National high blood pressure education program 2000)24                                                  
1. New onset hypertension defined as blood pressure of 140/90 
mmHg or higher after 20 weeks gestation.                                                                
2. New onset proteinuria defined as more than 300mg/24hrs or ≥1+ 
dipstick.  
 
CLASSIFICATION OF  PREECLAMPSIA 
1.  Mild preeclampsia 
2.  Severe preeclampsia   
There is no category as moderate preeclampsia  
 
 
 
 
  3
ACOG  CRITERIA FOR DIAGNOSIS OF SEVERE 
PREECLAMPSIA1 
1. Systolic blood pressure of 160mmHg or higher or diastolic blood 
pressure of 110mmHg or higher on 2 occasions at least 6 hours 
apart while the patient is in bed rest after 20 weeks gestation. 
2. Proteinuria of 5g or higher in a 24 hour urine sample or 3+ or 
greater on random urine sample collected at least 4 hours apart. 
3. Oliguria of less than 500ml in 24 hours. 
4. Pulmonary oedema. 
5. Impaired liver function. 
6. Thrombocytopenia. 
7. Fetal growth restriction. 
8. Cerebral or visual disturbance. 
9. Epigastric or right upper quadrant pain. 
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BLOOD PRESSURE MEASUREMENT 
Instrument 
1. Conventional mercury sphygmomanometer:  
- gold standard for blood pressure measurement.                
2. Electronic blood pressure monitor: 
- may under estimate the blood pressure. 
Technique 
• Women should be relaxed and resting for at least half an hour 
before blood pressure measurement.  
• Women should be seated or at 45° recline with the forearm 
horizontal and well supported and the arm at the level of heart 
with her feet supported or on the ground. 
• Right arm should be used with a cuff of appropriate size. 
• Korotkoff sound V should be used as a measure of diastolic blood 
pressure. 
• K5 is closer to the actual intra-arterial pressure, physiologically 
accurate, more reliably detected and reproducible.     
• K4   has limited reproducibility. 
• K4 /K5 difference is smaller in hypertensive than in normotensive 
pregnant women.  
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THEORIES ABOUT ETIOPATHOGENESIS OF 
PREECLAMPSIA 
1.  ABNORMAL PLACENTATION 
Failure of secondary wave of trophoblastic invasion into 
myometrial spiral arterioles results in reduced uteroplacental blood flow. 
The ensuing ischemia and hypoxia leads to aberrant expression of genes 
which encode for proinflammatory cytokines capable of eliciting 
endothelial dysfunction5. 
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2.  ENDOTHELIAL DYSFUNCTION 
Endothelial dysfunction resulting in 
a. Loss of vascular integrity is evidenced by elevated biomarkers of 
endothelial dysfunction such as plasma fibronectin and 
thrombomodulin12. 
b. Increased vascular reactivity results in generalised and intense 
vasospasm leads to reduced perfusion. This is due to  increase in 
vasoconstrictors thromboxane and endothelin and increased 
sensitivity to angitensin II and decrease in vasodilators nitric 
oxide and prostacyclin42. 
c. Activation of coagulation cascade.  
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3.  IMMUNOLOGICAL  FACTOR  
Immune  maladaptation in preeclampsia.  
a) Pathological lesions in placenta similar to acute graft rejection.  
b) Lower level messenger RNA for HLA-G8. 
c) Th1/Th2 response with Th2 dominance. Cytokines like tumour 
necrosis factor-α, interleukin-2 and 6 mediate immune 
maladaptation2. 
d) Impaired production of blocking antibodies. 
4.  GENETIC PREDISPOSITION  
Explained by both single gene model and polygenic inheritance. 
a) Tendency for preeclampsia is inherited6. 
b) Women heterozygous for the angiotensin gene variant T235 had a 
higher incidence of preeclampsia43. 
c) Association between HLA DR4 and preeclampsia17.  
d) Inherited thrombophilia predispose women to preeclampsia 
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5.  NUTRITIONAL FACTOR 
Mac Gillivray viewed the evidence for the role of dietary 
deficiency in the pathology of preeclampsia 
a) Obesity: C reactive protein is increased associated in turn with 
preeclampsia46. 
b) Ascorbic acid: Incidence of preeclampsia was doubled in women 
whose dietary intake of ascorbic acid was less than 85 mg48.  
c) Calcium deficiency: When concentration of calcium is low in 
extra cellular fluid amount of calcium entering the cell increases 
making vascular smooth muscle more sensitive to excitation. 
6.  OXIDATIVE STRESS 
a)  Preeclampsia may have its origin in a disturbed oxidative                         
mechanism. 
b)  Abnormal levels of lipid peroxidise in preeclamptic women 
inhibits prostaglandin synthetase. 
c)  Risk of preeclampsia increased in women with increased oxidised      
low density lipoprotein  and triglyceride32.    
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PATHOPHYSIOLOGY OF PREECLAMPSIA 
PRIMARY LEVEL 
Changes that occur in placenta and placental vascular bed are 
a) Relative lack of trophoblast infiltration into arterial wall during 
placentation. 
b) Endothelial damage, insudation of plasma constituents into vessel 
wall, proliferation of myointimal cells and medial   necrosis10.        
c) Acute atherosis. 
d) Obstruction of spiral arteriolar lumen by atherosis may impair 
placental blood flow29.   
e) Magnitude of defective trophoblast infiltration of spiral            
arterioles correlated with the severity of hypertensive disorder21.   
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SECONDARY LEVEL 
I.  Renal system 
a) Renal Pathology - glomerular capillary endotheliosis38 
b) Glomerular filtration rate and renal perfusion are decreased. 
c) Hyperuricemia is due to reduced renal clearance of uric acid7.   
d) Proteinuria indicates advanced disease with poor prognosis. 
e) Hypocalciuria is due to increased tubular resorption of calcium39.    
 
ii.  Cardiovascular system 
Cardiovascular dysfunction associated with preeclampsie are related to 
a) Increased cardiac afterload caused by hypertension. 
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b) Decreased cardiac preload by hemoconcentration. 
c) Endothelial activation with extravasation into the extracellular 
 space. 
1.  Hemodynamic changes 
a. Hyperdynamic circulation. 
b. Increased peripheral resistance. 
c. Decreased preload. 
d. Decreased cardiac output. 
e. Increased sensitivity to vasopressors. 
2.  Blood Volume Changes 
a) Hypervolemia of pregnancy is severely curtailed. 
b) Hemoconcentration due to generalised vasoconstriction and 
 endothelial  dysfunction with increased vascular permeability37.  
iii.  Hematological changes 
a) Microangiopathic hemolysis - caused by endothelial disruption 
with platelet aggregation and fibrin deposition, diagnosed by 
elevated levels of serum lactate dehydrogenase and peripheral 
smear schizocytosis9.   
b) Thrombocytopenia – due to platelet activation and aggregation16.  
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c) Platelet activating factor increased. 
d) Increased megakaryocytes and thrombopoetin. 
e) Deficiency of any soluble coagulation factors very uncommon 
unless another event coexist19. 
f) Thrombophilia is associated with early onset preeclampsia.  
g) Antithrombin III lowered.  
iv.  Hepatic changes 
a) Elevation of liver enzymes in severe preeclampsia. 
b) HELLP syndrome – hemolysis,elevated liver enzymes and low 
platelets44. 
c) Periportal hemorrhage in the periphery of liver. 
d) Hepatic artery resistance increased evidenced by sonography27.   
 
Specimen – Liver damage in severe preeclampsia. 
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v. Endocrine changes 
a) Renin, angiotensin II, aldosterone decrease to normal nonpregnant 
range45.  
b) Despite this women with preeclampsia avidly retain infused  
sodium. 
c) Vasopressin level increase despite decrease in plasma osmolarity. 
d) ANP levels increase in preeclamptic women. 
vi.  Fluid and electrolyte changes 
a) Extracellular fluid volume changes manifested as edema due to 
endothelial injury. 
b) Electrolyte concentration do not differ much. 
vii.  Uteroplacental perfusion 
a) Compromised uteroplacental perfusion from vasospasm is almost 
certainly a major culprit in the genesis of increased perinatal 
morbidity and mortality. 
b) Doppler velocimetry  measured higher impedance in peripheral 
than in central vessels – ring like distribution. 
 
   
 
 
Normal umbilical artery velocimetry 
 
 
Absent diastolic umbilical artery velocimetry 
            
Reversal of umbilical artery velocimetry 
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TERTIARY LEVEL                      
Tertiary systemic effects of preeclampsia are secondary to          
decompensation which can present as following 
a.  eclampsia                          g.  HELLP syndrome                  
b.  cerebral haemorrhage  h.  retinal detachment 
c.  pulmonary edema   i.  corneal edema 
d.  ARDS                       j.  laryngeal edema 
e.  DIC                          k.  hepatic  rupture 
f.  renal cortical necrosis  
 
 
 
 
 
Specimen - intracranial hemorrhage 
   
 
                             
CT Brain - Intracerebral hemorrhage 
                            
Hypertensive retinopathy 
  15
 
FETAL AND NEONATAL EFFECTS 
Preeclampsia is associated with increased perinatal morbidity and 
mortality. 
a. Fetal growth restriction. 
b. Intra uterine death. 
c. Still birth. 
d. Prematurity. 
e. Respiratory distress syndrome. 
f. Neonatal sepsis. 
 
 
 
 
 
IUGR  Baby      Preterm Baby  
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PREDISPOSING FACTORS OF PREECLAMPSIA 
1.  Age 
a)  Young primi  < 20 years. 
b)  All patients   > 30 years. 
2.  Parity and Paternity 
a) Primi have higher incidence than multipara (11.9% vs 4.7%). 
b) Protective effect of multipara is lost with change of partner31. 
c) Sperm exposure protects against preeclampsia. There is 2.4% 
increased risk for preeclampsia in contraceptive users. 
d) Incidence of preeclampsia in nullipara 3.2%, multipara with 
changed paternity 3% compared with 1.9% multipara without 
change in paternity40. 
e) Donor insemination is associated with 2 fold risk for  
preeclampsia. 
f) Oocyte donation is associated with increased risk for  
preeclampsia. 
g) Men who fathered a preeclamptic women were nearly twice as 
likely to father a preeclamptic pregnancy in a different women. 
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3.  Race 
a) Arab, Muslims, Jews show an increased risk for preeclampsia.  
b) Africo American ethnicity have an increased incidence. 
4.  Social status 
a) Low socio economic status are reported to have increased          
incidence of preeclampsia. 
b) Later studies showed that incidence was not different among, the  
five socio economic status. 
5.  Previous history of preeclampsia and interpregnancy interval 
a) The risk of preeclampsia in subsequent pregnancies is higher          
when it is severe earlier. 
b) Risk increases on increasing maternal age and interpregnancy         
interval.  
c) 13.1% risk of preeclampsia in second pregnancy, risk of 
preeclampsia in second increases with maternal age 1.3 per 5 year 
of increase in age. 
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6.  Family History 
a) Severe preeclampsia and eclampsia have a familial tendency. 3 
fold increase in preeclampsia and 4 fold increase of severe 
preeclampsia.  
b) 26% incidence of preeclampsia in daughters. 
c) Odds ratio 2.23 in full sisters, 1.6 in maternal half sisters and 1.8 
in paternal half sisters. 
7.  Pregnancy Associated 
a) Twin gestation: 4 fold increased risk of preeclampsia due to 
hyperplacentosis and relative placental ischaemia or 
immunological reaction to large placental mass. 
b) Molar pregnancy: Confined to large rapidly growing moles in       
which the incidence of preeclampsia is 70%, with small slowly 
growing moles there is no increased incidence of preeclampsia. 
c) Hydrops foetalis: Increased incidence of preeclampsia due to 
hyper placentosis. 
d) Congenital malformation: In triploidy the risk of preeclampsia is 
35% due to placentomegaly. 
 
  19
 
8.  Urinary tract infection 
This leads to increased production of inflammatory products, 
cytokines, free radicals and proteolytic enzymes causing endothelial 
dysfunction.  
9.  Obesity, insulin resistance, dyslipidemia 
a) BMI is an independent risk factor for preeclampsia. 
b) Adipocytes release tumour necrosis factor α aggravating cytokine 
mediated oxidative stress. 
c) Insulin resistance / hyperinsulinemia are associated with increased 
sympathetic activity and increased tubular reabsorption of 
sodium. 
d) Overt diabetes milletus 30% risk of preeclampsia especially when 
vascular changes are present. Odds risk increases by 20% per 
nmol/l increase in plasma glucose level.  
10.  Exogenous factors 
a) Smoking: decrease the incidence of preeclampsia due to direct        
effect on placental function and reduction in HCG and estradiol18. 
b) Psychosocial strain: working women had 2.3 times risk of 
preeclampsia than non working women. 
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11.  Underlying Disorders 
a) Sickle cell trait women at significant risk of preeclampsia20. 
b) Women with familial thrombophilia especially those with 
combined defects and antithrombin deficiency have increased risk 
not only of preeclampsia but also fetal loss. 
c) Hyper homocystenemia has 7times higher risk for preeclampsia11. 
d) Underlying renal disorder has 20%  risk of  preeclampsia. 
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MANAGEMENT OBJECTIVES IN SEVERE PREECLAMPSIA 
There is no preventive therapy against preeclampsia at present. 
Even though calcium, aspirin, magnesium, fish oil have been tried. 
Severe preeclampsia is associated with maternal complication like 
HELLP, eclampsia, pulmonary edema, abruption, fetal complication like 
IUGR, IUD, preterm delivery .As termination of pregnancy remains the 
only cure the primary objective in the management of severe 
preeclampsia is to effect timely delivery in order to  
• Prevent maternal morbidity and mortality. 
• Improve the perinatal and neonatal outcome. 
In all circumstance the wellbeing of mother is primary, in some 
cases delay seriously jeopardize the wellbeing of mother, fetus or both. 
Adopting expectant management in selected patients in a tertiary 
institution will improve the perinatal outcome without compromising 
maternal safety. Such an approach has been advocated by research 
workers in various part of world. 
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RANDOMISED CONTROLLED TRIAL AGGRESSIVE VERSUS 
EXPECTANT MANAGEMENT OF SEVERE PREECLAMPSIA 
REMOTE FROM TERM 
Odendaal et al25 at 1990 conducted the trial which included 58 
women with severe preeclampsia between 28-34 weeks randomised to 
aggressive and expectant group. Results of the trial showed that  in 
expectant management mean prolongation  was 7.1 days, lower 
incidence of neonatal complications, less need for neonatal ventilation 
and not associated with increased maternal complications. 
Sibai et al36 at 1994 randomised 95  patients with severe 
preeclampsia between 28-32 weeks to aggressive and expectant 
management. Expectant group was managed with bed rest, 
antihypertensive drugs and intense maternal and fetal monitoring. In 
expectant group average latency period was 15.4 days, had higher birth 
weight, higher gestational age at delivery, lower admission to NICU, 
lower neonatal complications and similar incidence of abruption.     
Visser et al41 at 1995 managed 254 patients with severe 
preeclampsia between 20-32 weeks  expectantly with the intention to 
prolong gestation. Outcome of the study was median prolongation of 14 
days and perinatal mortality rate 20.5%. They concluded the study that 
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expectant management may delay delivery and enhance fetal maturity 
and doesn’t appear to be associated with increased risk of maternal 
mortality and morbidity.  
Hall DR et al14 at 2000 did a 5 year prospective study to evaluate 
the perinatal outcome of early onset, severe preeclampsia in 340 
patients. Clinical and biochemical monitoring of maternal status with 
careful blood pressure control. Fetal surveillance included six hourly 
heart rate monitoring, weekly Doppler and ultrasound evaluation of the 
fetus every two weeks. Results of the study was  mean prolongation of 
11 days, neonatal survival rate of 94%, NICU care in 40.7% of cases, 
median NICU stay was 6 days. 81.5% cases were delivered by caesarean 
section, most common indication being fetal distress. There was no 
maternal death. They concluded that expectant management of early 
onset, severe preeclampsia led to high perinatal and neonatal survival 
rates.  However neonatal sepsis remains a cause for concern. 
Shear RM et al34 at 2005 conducted a retrospective study at 
Sainte-Justin hospital, Canada  which included 155 women with severe 
preeclampsia < 34 weeks managed expectantly. Outcome of the study 
was mean latency period of 5.3 ± 5.2 days. Perinatal mortality rate of 
3.9%.  Gestational age was the strong predictor of perinatal outcome. 
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Sibai BM et al35 at 2007 conducted a trial at university of 
Cincinnati, USA. 1677 women of gestational age between 24 and 34 
weeks underwent expectant management. Study showed that expectant 
management in a suitable hospital is safe and it improves the neonatal 
outcome. 
Sarasam DS et al33 at 2008 evaluated expectant management in 
35 women with early onset  severe preeclampsia between 24-34 weeks. 
The study results were mean prolongation of 9.2 days, higher Apgar 
score at 1 minute, lower mean days of hospitalisation in the neonatal 
intensive care unit, with a lower incidence of neonatal and maternal 
complications. The study recommended expectant management in 
patients with severe preeclampsia remote from term, after proper 
selection of patients and careful monitoring. 
Bombrys AE et al4 at 2009 did a retrospective analysis of 
expectant management of severe preeclampsia in 66 patients at 27- 34 
weeks gestation. All patients received corticosteroids. Median 
prolongation was 5 days. Birth weight <10% for gestational age in 27% 
neonates and < 5% gestational age in 8% neonates, supporting a role for 
such management in early onset severe preeclampsia. There was no 
eclampsia and 2 had transient renal insufficiency.  
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AGGRESSIVE VS EXPECTANT MANAGEMENT OF SEVERE  
PREECLAMPSIA REMOTE  FROM TERM  
(28 – 32 WEEKS) 
AIM OF STUDY   
• To compare merits and demerits of aggressive vs expectant 
management of women with severe preeclampsia remote from 
term (28-32 weeks)  
• To determine which is more beneficial by comparing perinatal 
and maternal outcome by statistical analysis  
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MATERIALS AND METHOD 
• Study Design : Prospective study  
• Study period : 2009-2010  
• Study Place  : Institute of obstetrics and gynaecology,Chennai. 
SAMPLE   
Group I   Patient of severe preeclampsia remote from term (28-34 
weeks) managed aggressively that is glucocorticoid 
treatment followed by delivery in 48 hours. All patients 
who delivered within 96 hours of admission were noted.  
Group II  Patients of same group treated expectantly i.e., 
glucocorticoid treatment followed by intensive maternal 
and fetal monitoring followed by delivery only for specific 
maternal and fetal indication beyond 96 hours   
SAMPLE SIZE 
100 patients in group I who delivered after 48 hours of steroid 
administration were compared with 100 patients of group II. 
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SELECTION CRITERIA   
INCLUSION CRITERIA   
1) Gestational age 28-32 weeks  
2) Severe preeclampsia defined as 
 i. Blood  pressure ≥ 160/110 mmHg with proteinuria ≥ 2+ 
 ii.  Blood pressure ≥  150/100 mmHg with proteinuria ≥ 3+ 
 iii. Blood pressure ≥ 140/90 mmHg with proteiniuria,   
  headache, oliguria.   
EXCLUSION CRITERIA  
1. Women with other medical complications  
2. Rupture of membranes  
3. Preterm labour  
4. Multifetal gestation  
5. Platelet count < 1,00,000 /mm3  or  HELLP syndrome  
6. Eclampsia  
7. Fetal congenital malformation  
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GUIDELINESS FOR EXPECTANT MANAGEMENT 
1. All patients are observed in labour room for atleast 24 hours to 
determine their eligibility for expectant management  
2. Magnesium sulfate for seizure prophylaxis for selected features  
3. Steroids are given to improve fetal outcome  
4. Anti-hypertensives are given to control blood pressure  
5. Complete blood count, liver and renal function test were done  
MATERNAL MONITORING  
• Blood pressure every 4-6 hours  
• Daily urine albumin  
• Daily weight, gravidogram, urine-albumin 
• Platelet count everyday  
• LFT alternate day  
• Serum uric acid biweekly  
• Input - Output monitoring  
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• 24 hour urinary protein weekly  
• Anti-hypertensive drugs  to control blood pressure in the range of 
systole : 130-150 mmHg, diastole : 80-100 mmHg,  
• Retinal changes.  
FETAL  
• Daily  Fetal Movement count  
• NST daily  
• USG – for fetal growth weekly  
• Doppler USG twice weekly   
Then,  
• Headache in preeclamptic women are treated with analgesic and 
bed rest.  
• If headache persisted, blood pressure is uncontrolled,  then 
decision is made for delivery and magnesium sulphate  started.  
 
 
  30
 
WHAT TO EXPECT OF EXPECTANT MANGEMENT  
At any time during the concerned period of prolonging pregnancy 
if contraindication to expectant management appears pregnancy is 
terminated either vaginally or abdominaly  
INDICATIONS FOR TERMINATION  
MATERNAL INDICATION 
• Uncontrolled blood pressure ≥ 160/110 mmHg despite maximum 
dose of anti-hypertensives for 4 days  
• Eclampsia  
• Platelet count < 1,00,000 / mm3  
• SGOT/SGPT more than 2 times the upper limit of normal with 
epigastric pain/tenderness  
• Pulmonary edema  
• Compromised renal function  
• Abruptio placenta  
• Persistent severe headache or visual changes  
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FETAL INDICATION 
• Repetitive late/variable deceleration  
• AFI ≤ 5  
• USG :  absent (or) reversal of diastolic flow in umblical artery, 
EFW < 5th centile    
MODE OF TERMINATION   
• LABOUR INDUCTION 
PGE2 gel  instillation for induction of labour - followed by 
oxytocin augmentation if needed.  
• LSCS   
GUIDELINES FOR AGGRESSIVE TREATMENT 
• All patients are observed in labour room  
• Mgso4  regime to selected patients for seizure prophylaxis  
• Steroids to improve fetal outcome followed by delivery in 48 
hours  
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• Anti-hypertensive for blood pressure  control, blood investigation 
done as like that of expectant management  
• USG for fetal well being – then labour is induced  by PGE2gel 
followed by oxytocin augmentation if needed.  
INTRAPARTUM MANAGEMENT   
 Preeclamptic women are more prone to  develop convulsion 
during labour than normotensive – hence if not intiated earlier 
Mgso4 initiated  during labour in selected cases  
 Input/output monitoring  
 If it is unripe LSCS to be considered because of high incidence of 
complications like abruption, fetal distress 
• Epidural/general anaesthesia for LSCS  
 Once cervix favourable augmentation given  
• Local infiltration for vaginal delivery  
• Fluid < 150ml/hr (if oliguria <10ml/hr  fluid and Mgso4 decreased 
accordingly)  
• Anti-hypertensive treatment  
• Goal : systolic Blood pressure 140-150 mmHg, diastolic Blood 
pressure  90-100 mmHg 
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POSTPARTUM MANAGEMENT  
• Intensive monitoring done for 2-4 days – vitals, reflex, input 
output monitoring     
• Blood Pressure  control  
• Prophylatic anticonvulsant not given  
• Patients are seen at weekly interval until her Blood pressure is 
normal without medication   
• If this change does’t not occur by 6 weeks, workup for 
hypertension made.       
 
OUTCOME 
 
• Prolongation of pregnancy  
• Perinatal outcome  
• Maternal outcome were evaluated   
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Incidence in the study period: 
 Total number of deliveries:24,700  
Mild preeclampsia:12% 
        Severe preeclampsia:1.3% 
          Eclampsia:0.4% 
 
Table 1 
Maternal age 
Age (Years) 
Aggressive 
(100)  
Expectant 
(100) 
16-19 16 13 
20-24             33            36 
25-29 29 27 
30-34 19 20 
35-40 03 04 
            
         Both groups were similarly matched with respect to  their age 
group. 33% cases in aggressive group and 36% cases in expectant group 
belonged to 20-24 years of age.      
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Table 2 
Parity 
Parity  Aggressive  Expectant  
Primi               61 68 
Second  24 28 
Third  10 03 
Fourth  04 01 
Fifth  01 - 
 
 Both groups  were similarly matched with respect to parity. Primi 
constituted 61% cases in aggressive group and 68% cases in expectant 
group. 
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Table 3 
Gestational Age on admission 
 
GA weeks Aggressive(100) Expectant(100) 
28-30 45 42 
31-32 55 58 
 
Both groups were similarly matched with respect to gestational 
age on admission. 55% cases in aggressive group and 58% cases in 
expectant group constituted 31-32 weeks gestational age, 
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28-30 31-32
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Aggressive Expectant 
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Table 4 
Analysis of past obstetric history  
 
Past H/o Preeclampsia Aggressive (39) Expectant (32) 
Present 15 12 
Absent  24 20 
 
38.4% cases in aggressive group and 37.5% cases in expectant 
group had recurrent preeclampsia. 
 
PAST HISTORY
0 5 10 15 20 25 30
Present
Absent 
Aggressive Expectant
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Table 5 
Analysis of Family History  
 
Family H/o Aggressive (100) Expectant (100) 
Not known/no history 85 89 
Mother preeclamptic 05 03 
Sister preeclamptic 10 08 
 
Only 15% cases in aggressive group and 11% cases in expectant 
group had family history of  preeclampsia. 
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Table 6 
Analysis of systolic blood pressure 
Systolic BP on 
admission(mmHg)
Aggressive(100) Expectant(100) 
140-149 32 29 
150-170 48 52 
>170 20 19 
 
Mean systolic blood pressure on admission was 157.42 mmHg in 
aggressive group and 157.38 mmHg in expectant group. 
P value: 0.98     Statistically insignificant. 
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Table 7 
Analysis of Diastolic Blood Pressure  
Diastolic BP on 
admission(mmHg)
Aggressive 
(100) 
Expectant 
(100) 
 90-100 39 28 
101-110 35 43 
111-120 23 25 
     >120 03 04 
 
Mean diastolic blood pressure on admission was 104.67 mmHg in 
aggressive group and 105.73 mmHg in expectant group. 
P value: 0.43  Statistically insignificant. 
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Table 8 
Initiation of magnesium sulphate  
MgSO4 Aggressive (100) Expectant  (100) 
Given  88 75 
Not given  12 25 
 
           88% cases in aggressive group and 75% cases in expectant group 
were given magnesium sulphate. 
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Table 9 
Retinal changes 
Fundus Aggressive (100) Expectant (100) 
Normal  80 82 
Grade I HTR 16 18 
Grade II HTR 04 - 
 
   20% cases in aggressive group and 18% cases in expectant group had 
hypertensive retinopathy 
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Table 10 
Maternal Outcome  
Complications  Aggressive Expectant  
AP IP PP Total AP IP PP Total 
Abruption  3 2 - 5 5 3 - 8 
HELLP / DIC  2 - - 2 1 2 - 3 
Eclampsia 1 - 2 3 1 - 1 2 
Renal failure  - - - - 1 - - 1 
Pulmonary oedema  - 1 - 1 1 - 1 2 
Cerebral oedema  - - - - - - 1 1 
Maternal death  - - - - - - - - 
Total  6 3 2 11 9 5 3 17 
AP-Antepartum, IP-Intrapartum, PP-Postpartum. 
11% major complications occurred in aggressive group while 17% 
complications in expectant group.  
Though complications rate are slightly higher, they are well managed by 
anaesthetist and ICU indicating institutional   supervision of expectant 
management. 
 It was found to be statistically insignificant.  
                         Chi square value: 2.08 
                         P value: 0.15 
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Table 11 
            Indications for termination in expectant group 
 Indications  Expectant (100)
Maternal  66 
Fetal  34 
                                            
          66% were terminated for maternal indications.  
          34% were terminated for fetal indications.  
 
INDICATIONS IN EXPECTANT GROUP
66
34
Maternal Fetal 
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Table 12 
Fetal indications for termination  
Indication 
Primi  
(68)  
Multi 
(32)  
Total  
(100)  
Perinatal 
Loss 
Severe oligohydraminos 08 03 11 05 
Persistent late 
deceleration                  
06 02 08 04 
IUGR <5th percentile  11 04 15 10 
Total 25 09 34 19 
 
Most common fetal indication being IUGR<5th percentile 
followed by severe oligohydramnios .                    
 55% perinatal loss in cases terminated for fetal indications.   
FETAL INDICATIONS IN EXPECTANT GROUP
Severe oligohydraminos Persistent late deceleration 
IUGR <5th percentile 
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Table 13 
Indications of termination in expectant group  
Maternal indication  
Indication 
Primi 
(68) 
Multi 
(32) 
Total  
(100) 
PN 
Loss 
Imminent 
symptoms  
22 10 32 09 
Abruption  05 03 08 02 
Uncontrolled BP 17 06 23 05 
Compromised 
 Renal function  
- 01 01 - 
Pulmonary  edema  - 01 01 - 
Eclampsia  01 - 01 - 
HELLP  01 - 01 01 
          Total 45 21 66 17 
PN- Perinatal 
Most common indication being imminent symptoms followed by 
uncontrolled blood pressure.        
 25% perinatal loss in cases terminated for maternal indications.   
 
   
 
 
MATERNAL INDICATIONS IN EXPECTANT GROUP
Imminent symptoms Abruption Uncontrolled BP
Compromised Renal Function Pulmonary  edema 
Eclampsia HELLP 
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Table 14 
Labour induction  
Mode 
Aggressive Expectant  
Primi 
(61) 
Multi 
(39) 
Total 
(100) 
Primi
(68) 
Multi 
(32) 
Total
(100) 
PG E2 gel  52 33 75 53 19 72 
Not induced due to 
maternal / fetal 
causes  
09 16 25 15 13 28 
 
75% cases were induced in aggressive group. 
72% cases were induced in expectant group. 
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Table 15 
Mode of delivery  
Mode  
Aggressive Expectant  
Primi 
(61)  
Multi 
(38)  
Total 
(100)  
PN loss
(63) 
Primi 
(68) 
Multi 
(32) 
Total 
(100) 
PNLoss
(36) 
Vaginal  48 31 79 51 42 20 62 27 
LSCS 13 08 21 12 26 12 38 09 
PN-Perinatal         
 
• 21%  LSCS in aggressive group whereas 38%  LSCS in expectant          
group.            
• As salvagability and fetal weight were lower in aggressive group,         
vaginal delivery preferred. Increased LSCS in expectant group 
was due to increased post ceaserean pregnancy. 
• Perinatal loss in LSCS was 57% in  aggressive group and 23.6% 
in expectant group. 
• Chi square value : 1.41 
 P = 0.23  Statistically insignificant.        
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Table 16 
Indication of LSCS in Aggressive group  
Indication Primi  Multi Total   
Perinatal 
Loss 
Post LSCS - 04 04 02 
Non reassuring 
CTG 
03 02 05 03 
Malpresentation  01 - 01 01 
Failure to progress 
unfavourable cervix 
07 01 08 04 
Abruption  02 01 03 02 
Total  13 08 21 12 
 
• Most common indication was Failure to progress/unfavourable 
cervix. 
• Among 50% multipara the indication was post cesarean 
pregnancy. 
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Table 17 
Indication of LSCS in Expectant group  
Indication Primi  Multi Total   
Perinatal 
Loss 
Post LSCS _ 07 07 01 
Non reassuring CTG       10 02 12 03 
Malpresentation  03 _ 03 _ 
Failure to progress 
unfavourable cervix 
11 02 13 03 
Abruption  02 01 03 03 
Total 25 12 37 09 
 
• Most common indication was failure to progress/unfavourable 
cervix. 
• Among 58.3% multipara the indication was post cesarean 
pregnancy. 
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Table 18 
Perinatal outcome in latency interval <96 hr  
 
Latency interval 
(hours) 
Cases Perinatal Loss 
< 24 31 23 
24-48 27 19 
49-72 53 34 
73-96 47 27 
 
• 58 patients who were delivered before 48 hours of steroid were not 
compared.  
• 100 patients who were terminated after 48 hours of steroid were 
compared in our study.  
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Table 19 
                Prolongation of pregnancy in Expectant Group 
Latency interval 
(Days) 
Cases Perinatal Loss 
<5 23 16 
5-8 40 13 
9-12 29 05 
13-20 06 02 
>20 02 - 
Total              100 36 
 
Maximum prolongation was 23 days. 
Median prolongation was 7 days. 
Mean prolongation was 7.54 days 
P value<0.001 Statistically significant. 
As the latency interval increased perinatal loss decreased. 
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Table 20 
Fetal outcome  
Fetal outcome 
Aggressive Expectant  
Primi Multi Total Primi Multi Total  
Total Birth  61 39 100 68 32 100 
Live Birth  45 31 76 60 27 87 
Still Birth  16 8 24 10 3 13 
Neonatal Death  28 11 39 17 6 23 
Perinatal Death  44 19 63 27 9 36 
 
Perinatal loss includes both still birth and early neonatal death.                        
Perinatal loss in aggressive group: 63% 
Perinatal loss in expectant group: 36% 
For live born 
   Chi square value: 4.01                     Degree of freedom: 1                                 
P value <0.05   Statistically significant. 
For perinatal loss 
Chi square value: 14.58                   Degree of freedom: 1  
P value<0.001 Statistically  very high significance. 
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Table 21 
Birth weight specific death 
 
Birth 
weight (Kg) 
Aggressive  Expectant  
Born  Death  Born  Death  
<1 12 12 06 06 
1.00-1.25 36 28 16 12 
1.26-1.50 28 15           16 08 
1.51-1.75 16 06 34 08 
1.76-2.00 06 02 16 02 
2.01-2.25 02 _ 12             _ 
Total  100           63 100          36 
 
Mean birth weight was 1.33 kg in aggressive group and 1.61 kg in 
expectant group. 
Pvalue <0.001 Statistically significant. 
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Table 22 
Gestational Age specific perinatal mortality  
 
Gestation 
Age 
(Weeks) 
Aggressive  Expectant  
Born  Death  Born  Death  
28-30 39 32 22 14 
31-32 58 31 32 18 
33-34 03 _ 45 04 
Total  100 63 100 36 
 
Mean  gestational age at delivery was 30.55 weeks in aggressive 
group and 31.64 weeks in expectant group. 
Chi square value: 8.94 
P value< 0.01 Statistically significant. 
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Table 23 
Neonatal hospitalisation  
 
Live Babies  Aggressive (76) Expectant (87) 
Admission to NICU 76 87 
Neonatal Death  39 23 
Survival 
hospital 
stay (Days)
 
  
< 5 03 20 
5-10 10 21 
11-15 09 14 
> 15 15 09 
Total survival  37 64 
Survival rate  48.6% 73.5% 
 
Mean hospital stay was 9.6 days in expectant group whereas in 
aggressive group it was 13.4 days.  
Total survival was 37 babies in aggressive group. 
Total survival was 64 babies in expectant group.  
Chi square value:14.58 
P value<0.001  Statistically significant. 
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DISCUSSION 
• Incidence of preeclampsia is 5 – 8% according to ACOG 2002. 
• Incidence of preeclampsia in IOG is 12%  
• Incidence of severe preeclampsia in IOG is 1.3%   
• There were 258 cases of severe preeclampsia  remote from term 
28 – 32 weeks in our study. 200 patients got full dose of steroids 
and they were assigned as either aggressive or expectant group.   
• 62.5% patients were in the age group 20- 29 years  
• 64.5% of severe preeclamptic women were primi  
• Recurrent preeclampsia in 37.9% patients  
• 8% patients had mother with preeclampsia  
• 18% patients had sister with  preeclampsia  
• Mean systolic blood pressure was 157.4 mmHg 
• Mean diastolic blood pressure was 105.2  mmHg 
Likelihood of developing preeclampsia is increased according to  
BJOG Oct 2003 
• Primi. 
• Age >30. 
• Family history. 
• BMI >35.                                               
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Sibai et al showed risk of developing preeclampsia in next 
pregnancy being 45.5% out of them 21% go for severe preeclampsia. 
INDICATION FOR TERMINATION 
  Study                                   maternal indication    fetal indication 
a. Blackwell SC3 & others ‘02      80.0%                         30.0% 
b. Hall DR, Odendaal HJ15 ‘00      55.0%                         45.0% 
c. Our study                               66.0%        34.0% 
Most  common   maternal  indication  being  imminent  
eclampsia. Our  study  values  are  in  between  the  both  studies  
available. 
MODE OF DELIVERY 
Though mode of delivery had not shown to influence the fetal 
outcome, LSCS rate was higher in expectant group. 
 Study                                             Vaginal               LSCS 
a. Hall BR & Odendaal HJ15 2000  18.5% 81.5% 
b. Nasser et al23 1998                                48.3% 51.7% 
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c. Murphy DJ, Stirrat M22 2000           20.0%         80.0% 
d. Railton A & Allen DG28 1987     25.0% 75.0% 
e. Our study                                     62.0%     38.0% 
 Our study is similar to Nasser study. 
PROLONGATION OF PREGNANCY 
Study                            Mean prolongation of pregnancy  
a. Odendaal HJ et al25 1990              7.1 days 
b. Sibai et al36 1994    15.4 days 
c. Vissur&wallenberg41 1995        14 days 
d. Yong, Li R47                         11days (28-31weeks) 
       08days (32-33weeks) 
e. Railton A, Allen DG28 1987      11.4 days 
f. Olah KS Redman CW26               9.5 days 
g. Murphy DJ&Stirrat GM222000   14 days 
h. Our study                             7.54days                                            
 Our study similar to Odendaal HJ’study. 
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MATERNAL OUTCOME 
Comparison of major complications in both the group. 
Study                               Complications   
a. Odendaal et al25 1990            No increase in complication. 
b. Sibai et al36 1994                     No increase in complication. 
c. Hall et al15 2000   No maternal death. 
3 needed ICU. 
1 needed dialysis. 
d. Haddad B Deis S13 2004             No maternal death or eclampsia. 
                                                  Morbidity similar in both groups. 
e. Railton A, Allen DG28 1987       23.2% had increase in major                         
      complications. 
f. Our study 2010   11.0%  in aggressive 18.0% in  
       expectant group. Statistically   
      insignificant. 
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MATERNAL COMPLICATIONS 
Study Abruption
Pulmonary
edema 
HELLP Eclampsia 
renal 
failure 
Hall and 
collegues15 2000 
20% 2% 5% 1.2% 0.3% 
Vissur& 
Wallenberg411995 
5% -- -- 1.9% -- 
Murphy 
DJ&Stirrat GM22 
2000   
1.5% -- 21% 1.4% 1.3% 
Olah KS Redman 
CW geeth26 93 
-- -- 14.2% -- .5% 
Our study  8% 2% 3% 2% 1% 
 
Our study showed relatively low incidence of abruption and 
HELLP than Hall’s study. No maternal death in our study. 
• Among 3 patients complicated by HELLP/DIC, 2 patients had 
coagulopathy with prolonged clotting time bleeding from wound 
on table and they were treated with FFP and platelet transfusion. 
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Third   patient who developed HELLP was terminated and treated 
with 8 units platelets. 
• 1 patient who had compromised renal function was treated  
conservatively under nephrologist guidance   
• 1patient developed postpartum eclampsia on 2nd post operative 
day and was started on magnesium sulphate. 
• 2 patients developed pulmonary edema and were treated 
vigorously under anaesthetist supervision. 
These situations explain the necessity of intensive care facilities 
in the management severe preeclampsia.Hemodynamic monitoring plays 
a major role in the treatment and trained persons and anaesthetist were 
available all the time for central vein catheterisation and monitoring. 
PERINATAL OUTCOME 
i) Perinatal mortality 
Study                              Perinatal loss  
a. Railton A, Allen DG28 1987                24.5% 
b. Odendaal HJ25   2000          22.3% 
 
c. Hall DR15 2000     24.0% 
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d. Murphy DJ & Stirrat GM22 2000  30.0% 
e. Haddad B, Dies S13 2004                      10.7% 
f. Our study                                            36.0% 
 Our study is similar to Murphy’s and is closer to 3 other studies. 
ii. Birth Weight 
Study                             Aggressive     Expectant  
a. Sibai et al36 1994                       1.2kg                1.62kg 
b. Our study                                1.33 kg              1.61kg 
 Our study correlated with Sibai et al and all others studies, 
showed  higher birth weight by expectant management. 
iii. Survival rate 
Study                            Aggressive       Expectant  
a. Sibai et al36 94                  24.0%                    65.0% 
b. Hall DR15 2000            70.0%               94.0% 
c. Our study                  48.6 %                 73.5% 
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Railton A, Allen DG 1987 showed 100% Survival rate of babies 
 born > 30 weeks in either group. 
Our study showed higher Survival rate in babies of higher 
 gestational age and birth weight and it was between both studies. 
iv. Neonatal complications 
Study         Hospital Stay(days) 
              Aggressive       Expectant  
a. Sibai et al36 94               30.6              20  
b. Olah KS26 93            >15               7.4 
c. Our study              13.4               9.6  
Our study showed expectant management babies had highest 
survival rate and lower neonatal complications. In this study admission 
was higher than that of Sibai et al because of lower birth weight but 
hospital stay as that of Olah due to advancement of neonatal care in the 
past 2 decades.                        
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SUMMARY 
In our study 100 patients with severe preeclampsia 28-32 weeks 
who were managed aggressively were compared with 100 patients with 
severe preeclampsia 28-32 weeks who were managed expectantly and 
following parameters were analysed. 
¾ Majority of the patients around 62.5% belong to the age group 
between 20-29 years. 
¾ Almost two third (62.5%) patients were primi. 
¾ Mean gestational age on admission was 31 weeks. 
¾ 37.9% patients had recurrent preeclampsia. 
¾ 26% patients had family history of preeclampsia. 
¾ Mean systolic blood pressure was 157.4mmHg and mean diastolic 
blood pressure was 105.2mmHg. 
¾ Majority of the patients had normal fundus. Around one fifth 
(19%) had hypertensive retinopathy. 
¾ Majority of the patients were given magnesium sulphate. 
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¾ Though major maternal complications were higher in expectant 
group it was proved to be statistically insignificant ( P =0.15). 
¾ 8 patients had abruption,  3 patients had DIC, 2 patients had 
eclampsia, 2 patients had pulmonary oedema and no maternal 
death. 
¾ 66% patients were terminated for maternal indications and 44% 
patients were terminated for fetal indications. 
¾ Though LSCS rate was higher in expectant group (38% vs 21%) 
but this was attributed to increased fetal salvagability and post 
caesarean pregnancy in expectant group. 
¾ Mean prolongation of pregnancy was 7.54 days. 
¾ Perinatal loss was significantly lower in expectant group 36% vs 
63%  proved to be statistically significant (P<0.001). 
¾ Perinatal loss was not influenced by LSCS. Perinatal loss in LSCS  
was 57.0% and 36.8% in aggressive and expectant group. 
¾ Perinatal loss was higher in the patients delivered <48 hours of 
steroid. 
¾ Mean birth weight was higher in expectant group (1.33kg vs 
1.58kg). It was found to be statistically significant (p<0.001) . 
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¾ Mean gestational age at delivery was higher in expectant  group 
(31.64 vs 30.55 weeks). It was found to be statistically significant 
(p<0.01) . 
¾ Expectant group had lower mean stay of hospitalisation(9.6 vs 
13.4 days). 
¾ Babies in expectant group had higher survival rate(73.5% vs 
48.6%). It was found to be statistically significant (p<0.001) . 
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CONCLUSION 
The expectant approach for management of  severe preeclampsia 
remote from term results in better obstretic outcome in the form of  
a. Lower perinatal mortality. 
b. Higher perinatal & neonatal survival  
c. Lower neonatal complications. 
d. Higher birth weight. 
e. Without increased maternal morbidity and mortality  
The success rate of expectant management depends on both 
gestational age and maternal and fetal condition at the time of 
admission. Since maternal and perinatal complications are significantly 
increased in these patients, expectant management should be done only 
in well selected patients only at tertiary centres where adequate maternal 
and neonatal intensive care facilities are available.   
Expectant management delays delivery and enhance fetal maturity 
and does not appear to be associated with increased risk of  maternal 
morbidity and mortality 
  
 
PROFORMA 
 
Name    :    Obstetric score: 
Age     :   LMP :   
Address   :                       EDD :  
Ip. No    :    Blood group: 
Occupation   :    Ht :          Wt:  
Booked/ not    :    HIVstatus:                 
Referred/not            : 
Complaints    
Present h/o   :  
period of amenorrhea                       pain abdomen  
edema feet                        vomiting  
headache                        oliguria  
bluring of vision                       palpitation  
Present Pregnancy     
I trimester    
II trimester  
III trimester  
  
 
Past  obstetric history 
Medical history  
Family history  
General Examination :  
Temperature         :   CVS  :  
Pulse rate           :    RS     :  
Blood pressure    :    CNS  :  
Respiratory rate   :   
BMI    :      
Edema    :  
Anaemia    :  
Per abdomen  :    
 
 
Pervaginal  :    
 
  
 
Investigation  
  Urine  - albumin:   :                      Hb   :  
      sugar          :                         Pcv   :  
                  Platelet     :   
 Blood  - sugar         :    LFT          :   
      urea           :  
      creatinine  :  
      uricacid     : 
      electrolyte :      
Ultra sound :  
Anti-hypertensive :  Drug :   dose :  
Gravidogram    
 Date   U/A    Wt   Sfh   AG   BP   Immiment  symptom 
Mgso4 : 
     Time   Dose   Temp   RR   I/O   DTR    PERL   U/A      
Maternal complications :  
Mode of induction :  
Indication for termination : Maternal / fetal 
Vaginal delivery  / LSCS  
  
 
 
Latency interval:  
Intra/ post partum complications 
Baby :  alive / still birth      
              gestational age 
 birth weight                            
            apgar score  
 admitted / not 
Follow up :  NICU stay 
Neonatal complications   
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ABBREVIATION 
ACOG - American College of Obstetrics and  
  Gynecology 
ANP   - Atrial natriuretic peptide 
ARDS        -         Acute respiratory syndrome 
BJOG  - British Journal Obstetrics andGynecology 
CTG   - Cardiotocography 
DIC                        -         Disseminated intravascular coagulation 
HCG                      -         Human chorionic gonodotropin 
HLA           -         Histocompatability antigen 
IUGR                     -         Intra uterine growth restriction 
LFT                        -         Liver function test 
LSCS   - Lower segment caesarean section 
NICU                     -         Neonatal intensive care unit 
NST   - Nonstress test 
USG   - Ultrasonography  
 
 
  
 
MASTER CHART - AGGRESSIVE GROUP 
 
S. No Age Parity Past History 
Family 
History 
Blood 
Pressure 
(mmHg) 
MGSO4 Fundus Induction 
Latency 
(Hours) 
Mode of 
Delivery 
Indication 
Gestational 
Age (Weeks) 
Birth 
Weight 
(KG) 
Alive / 
Stillbirth 
NICU 
stay 
(days) 
Maternal 
Complications 
1 19 E B B 142/112 A A A 70 A - 32 1.7 A 10 - 
2 22 B B B 154/90 B A B 53 B A 31 1.27 A A - 
3 25 A - A 158/102 A A B 73 A - 29 1 A A - 
4 20 A - B 170/92 A A A 82 A - 31 1.2 A A A 
5 27 A - B 172/120 A C A 52 B E 32 1.38 B - - 
6 17 B B B 144/104 A A A 86 A - 30 1.24 A A - 
7 23 C A B 160/94 A A B 68 A - 32 1.78 A 11 - 
8 24 B B B 172/96 A A A 90 A - 29 1.1 B - - 
9 18 A - B 142/106 A B A 78 A - 28 1.16 B - - 
10 26 A - A 152/122 A B A 54 B D 31 1.45 A 13 - 
11 20 A - B 166/108 A A A 80 A - 32 2.1 A 4 - 
12 25 B A B 164/118 A A B 87 A - 31 1.24 A 16 - 
13 19 A - B 146/110 A A A 60 A - 31 1.3 B - B 
14 22 A - B 156/98 A A A 85 A - 29 1.15 A A - 
15 31 A - B 176/100 A A A 67 B B 31 1.22 A A - 
16 21 C B A 148/114 A A A 89 A - 30 1.25 A 15 - 
17 32 B B B 168/102 A A B 65 A - 32 1.62 B 9 - 
18 23 A - B 150/98 A A B 77 A - 32 1.58 A A - 
19 17 A - B 140/108 A A A 49 A - 29 1.18 B - - 
20 33 D A B 174/92 A A A 56 A - 31 1.42 A 17 - 
21 17 C B B 150/120 A A B 53 B A 32 1.28 B - - 
22 22 B B B 142/110 A B A 78 A - 31 1 A A - 
23 21 A - A 160/94 A A A 86 A - 31 1.2 A A - 
24 25 B A B 148/114 A C A 68 A - 30 1.24 B - - 
25 19 A - B 174/90 A A B 87 A - 32 1.7 A 7 - 
  
 
S. No Age Parity Past History 
Family 
History 
Blood 
Pressure 
(mmHg) 
MGSO4 Fundus Induction 
Latency 
(Hours) 
Mode of 
Delivery 
Indication 
Gestational 
Age (Weeks) 
Birth 
Weight 
(KG) 
Alive / 
Stillbirth 
NICU 
stay 
(days) 
Maternal 
Complications 
26 22 A - B 172/108 A A A 70 B D 31 1.65 A 8 - 
27 26 A - B 158/98 A A A 79 A - 32 1.4 A A - 
28 18 B B B 144/106 A A A 54 A - 29 1.12 B - - 
29 20 D A B 152/94 B A B 90 A - 33 1.8 A 4 - 
30 23 A - B 162/90 A A A 92 A - 32 1.48 A 12 - 
31 27 A - B 168/126 A B A 59 B E 28 1.18 B - A 
32 32 A - A 148/96 B A A 65 A - 32 1.45 A 9 - 
33 16 A - B 176/116 A A A 91 A - 31 1.2 A 17 - 
34 22 B B B 164/104 A A B 85 A - 31 1.55 A 11 - 
35 26 A - B 154/92 A A A 50 A - 28 1.12 A A - 
36 20 C B B 146/102 B A A 89 A - 31 1.34 A 14 - 
37 25 A - B 162/118 A B A 64 A - 29 1.2 B - - 
38 24 A - B 156/106 A A A 75 A - 32 1.63 A A - 
39 19 A - B 176/108 A A A 52 B D 28 1.26 B - - 
40 30 B A B 140/100 B A B 58 A - 31 1.23 A A B 
41 20 B B B 140/96 B A A 52 A - 32 1.33 A A - 
42 25 A - B 160/116 A B A 58 B B 29 1.24 A A - 
43 19 A - B 176/102 A A A 64 A - 30 1.2 B - - 
44 26 C A B 162/90 B A A 66 A - 32 1.64 A 6 - 
45 27 A - A 144/106 A A B 58 A - 30 1.2 A 18 C 
46 22 A - B 164/94 A A A 79 A - 30 1.4 A 17 - 
47 30 B B B 172/108 A A B 83 B A 31 1.25 A 16 - 
48 19 D A B 168/104 A A A 85 A - 30 1.25 A 19 - 
49 21 A - B 158/96 A A A 50 A - 32 1.76 A A - 
50 16 A - B 146/118 A B A 91 A - 28 1.21 B - - 
51 22 A - B 154/110 A A A 83 A - 31 1.28 B - - 
52 32 A - B 166/98 A A A 68 A - 30 1.25 A 20 A 
  
 
S. No Age Parity Past History 
Family 
History 
Blood 
Pressure 
(mmHg) 
MGSO4 Fundus Induction 
Latency 
(Hours) 
Mode of 
Delivery 
Indication 
Gestational 
Age (Weeks) 
Birth 
Weight 
(KG) 
Alive / 
Stillbirth 
NICU 
stay 
(days) 
Maternal 
Complications 
53 23 B B A 148/108 A A B 76 A - 29 1.08 B - - 
54 20 A - B 170/120 A A A 71 B D 32 1.68 A A - 
55 26 A - B 142/106 A B A 85 A - 31 1.5 A 16 - 
56 25 A - B 174/100 A A A 69 A - 29 1.12 A A - 
57 33 C A B 152/114 A C B 92 B B 32 1.72 A 8 - 
58 17 B B B 156/104 B A A 76 A - 31 1.22 A A - 
59 24 A - B 144/90 B A B 70 A - 31 1.46 A 17 - 
60 29 A - A 174/98 A A A 70 B C 30 1.12 A A - 
61 18 D B B 144/112 A B A 58 A - 31 1.38 A 17 - 
62 24 B B B 172/94 A A A 79 A - 32 1.53 A A - 
63 21 A - B 154/102 A A A 80 A - 32 1.47 B - A 
64 22 A - A 140/92 B A A 62 A - 31 1.26 A B - 
65 26 A - B 148/104 A A A 82 A - 29 1.8 A A - 
66 22 C A B 156/100 A A B 56 A - 32 1.64 A 7 - 
67 25 A - B 152/114 A A A 88 B D 28 0.9 A A - 
68 24 B B B 148/108 A A A 49 A - 29 0.85 B - - 
69 16 A - B 174/94 A A B 53 A - 31 1.22 A A - 
70 20 A - B 150/110 A A A 69 A - 28 0.95 B - - 
71 22 A - B 160/124 A B A 87 B D 32 1.9 A 16 - 
72 26 A - B 162/128 A A A 48 A - 31 1.28 A A - 
73 27 C A A 146/98 A A B 77 A - 33 2.2 A 4 - 
74 23 B B B 176/118 A A A 70 B D 32 1.44 A 11 - 
75 25 B A B 164/106 B A B 74 B B 29 0.98 A A - 
76 35 A - B 144/96 A A A 50 A - 32 1.72 A 5 E 
77 20 A - A 166/98 A A B 78 A - 28 0.9 A A - 
78 32 A - B 178/120 A A A 84 A - 28 0.75 B - - 
79 23 B B B 142/92 A B A 52 A - 31 1.3 A A - 
  
 
S. No Age Parity Past History 
Family 
History 
Blood 
Pressure 
(mmHg) 
MGSO4 Fundus Induction 
Latency 
(Hours) 
Mode of 
Delivery 
Indication 
Gestational 
Age (Weeks) 
Birth 
Weight 
(KG) 
Alive / 
Stillbirth 
NICU 
stay 
(days) 
Maternal 
Complications 
80 27 C A B 140/116 A A A 64 A - 31 1.35 A - - 
81 28 A - A 144/110 A B A 77 B D 29 0.82 A - - 
82 29 B B B 172/102 A A A 58 A - 30 1.55 A - - 
83 30 A - B 160/120 A C A 83 A - 28 0.78 B - C 
84 31 A - B 158/92 A A A 86 A - 32 1.3 B - - 
85 33 A - B 146/104 A A B 51 A - 28 0.9 A A - 
86 34 B A A 156/98 A A B 70 A - 33 1.82 A 18 - 
87 28 A - B 142/114 A B A 86 A - 29 0.85 A A - 
88 33 A - B 174/106 A A A 52 A - 28 0.8 B - - 
89 32 B B A 160/94 A A A 49 A - 30 0.95 A A - 
90 40 A - B 170/90 A A A 63 A - 32 1.69 A 11 - 
91 28 A - B 140/98 A A B 73 A - 31 1.18 A A - 
92 38 A - B 176/112 A A A 88 B B 32 1.5 A 8 - 
93 30 B B A 166/108 A A A 56 B A 31 1.41 A 13 C 
94 34 A - B 158/100 A A A 91 A - 30 1.25 A 21 - 
95 33 A - B 140/104 B A A 64 A - 32 1.52 A A - 
96 29 B A B 172/118 A B B 78 B E 30 1.27 A 20 - 
97 32 A - B 148/96 A A A 53 A - 31 1.08 A A A 
98 28 C B B 154/110 A A A 51 A - 31 1.26 B - - 
99 28 A - - 152/112 A B A 64 A - 31 1.2 A A - 
100 26 A - - 160/114 A B A 58 A - 31 1.22 A A - 
 
 
 
 
 
  
 
MASTER CHART – EXPECTANT GROUP 
S.No Age Parity 
Past 
History Family 
History 
Blood 
Pressure 
(mm Hg) 
MGSO4 Fundus Induction Latency Days 
Mode of 
Delivery Indication 
Gestational 
Age (Weeks) 
Brith 
Weight 
(KG) 
Alive/ 
Stillbrith 
NICU 
Stay 
(days) 
Maternal 
Complications 
1 19 A - B 172/112 A B A 21 B C 33 2.15 A 3 - 
2 24 B A B 154/110 A A A 8 A - 34 1.72 A 10 - 
3 35 B B B 158/90 B A B 5 B B 33 1.77 A 11 - 
4 25 A - A 144/108 B A A 3 B B 32 1.27 A A - 
5 33 B B B 154/114 A B A 7 A - 31 1.56 A 12 - 
6 22 A - B 140/98 B A A 4 A - 28 0.85 B - - 
7 26 A - B 176/106 A A A 3 A - 32 1.50 A 9 A 
8 16 A - B 142/120 A B B 4 B D 31 1.45 A 18 - 
9 24 A - B 156/94 A A A 4 A - 31 1.51 A A - 
10 34 B A B 148/96 B A B 6 A - 33 1.62 A 10 - 
11 31 A - B 172/116 A A A 4 A - 31 1.40 A 16 D 
12 21 A - B 160/102 A A B 23 B D 34 2.20 A 4 - 
13 27 A - B 164/100 A A A 4 B C 28 1.10 A 17 - 
14 36 D A B 146/104 B A A 12 A - 33 1.76 A A - 
15 20 A - B 168/118 A A A 3 A - 30 1.26 B - E 
16 28 A - B 174/106 A A B 9 B D 34 1.75 A 15 B 
17 18 A - B 164/94 A A A 8 A - 34 1.78 A 5 - 
18 23 A - B 160/102 A A A 20 B B 33 2.10 A 2 - 
19 32 B B A 144/124 B B B 3 B A 29 1.20 A A - 
20 33 B B B 162/112 A A A 8 B A 33 2.18 A 4 - 
21 23 A - B 156/110 A A B 17 B E 31 1.26 B - A 
22 25 A - A 174/98 A A A 8 A B 34 2.00 A 2 - 
23 20 A - B 142/108 B A A 4 A - 29 0.850 B - - 
24 17 A - B 178/114 A A B 3 B D 30 1.50 A 17 - 
25 24 A - B 140/90 B A A 6 A - 33 1.58 A A - 
  
 
S.No Age Parity 
Past 
History Family 
History 
Blood 
Pressure 
(mm Hg) 
MGSO4 Fundus Induction Latency Days 
Mode of 
Delivery Indication 
Gestational 
Age (Weeks) 
Brith 
Weight 
(KG) 
Alive/ 
Stillbrith 
NICU 
Stay 
(days) 
Maternal 
Complications 
26 28 A - B 154/100 A A A 18 B B 34 2.10 A 02 B 
27 34 C A B 144/120 A B B 10 A - 32 1.62 A 12 - 
28 27 A - B 166/106 A A A 11 A - 33 1.78 A 9 - 
29 21 A - B 158/94 B A A 12 A - 32 1.62 A 15 - 
30 18 A - B 176/104 A A B 4 B D 34 1.36 A A - 
31 29 B A B 146/116 A A A 5 A - 33 1.70 A 16 - 
32 30 B B A 162/102 A A B 4 A - 28 1.00 B - E 
33 26 A - B 170/126 A B A 9 A - 34 1.86 A 8 - 
34 37 C A B 144/106 B A A 3 B E 30 1.12 B - A 
35 20 A  - B 154/96 B A A 5 B B 31 1.24 A A - 
36 31 B B B 152/108 A A B 3 A - 33 1.65 A 14 - 
37 19 A - B 176/92 A A A 18 A - 34 2.20 A 3 - 
38 22 A - B 140/118 A B A 7 A - 31 1.20 A A - 
39 31 B B B 168/92 A A A 10 A - 32 1.59 A A - 
40 24 A - B 176/114 A B B 11 B D 33 1.88 A 9 - 
41 27 A - B 140/108 B A A 4 A - 31 1.26 B - A 
42 29 A - B 142/90 B A A 9 A - 34 1.64 A 10 - 
43 18 A - B 164/112 A A B 19 B D 30 2.20 A 2 - 
44 23 A - B 146/110 A A A 10 A - 34 1.70 A A - 
45 30 B A B 180/120 A B B 8 B A 34 1.49 A 15 - 
46 20 A - B 158/106 A A A 6 B B 30 1.25 A 14 F 
47 39 B B A 170/94 A A B 9 A - 33 1.90 A 4 - 
48 22 A - B 160/104 A A A 5 A - 31 1.47 A 17 A 
49 33 C B B 140/116 A A A 8 A - 34 2.15 A 2 - 
50 28 B B B 154/102 A A B 3 B D 29 1.08 A A - 
51 18 A - B 156/96 B A A 12 A - 33 1.66 A 8 - 
  
 
S.No Age Parity 
Past 
History Family 
History 
Blood 
Pressure 
(mm Hg) 
MGSO4 Fundus Induction Latency Days 
Mode of 
Delivery Indication 
Gestational 
Age (Weeks) 
Brith 
Weight 
(KG) 
Alive/ 
Stillbrith 
NICU 
Stay 
(days) 
Maternal 
Complications 
52 26 A - B 178/102 A A A 4 A - 30 1.24 A 13 C 
53 21 A - B 142/98 B A A 11 B - 34 1.98 A 4 - 
54 25 A - A 152/118 A B A 7 B B 29 1.48 A 10 - 
55 19 A - B 144/104 B A A 3 A - 28 .950 B - - 
56 24 A - B 174/100 A A B 9 B C 31 1.50 A 20 - 
57 32 B A B 156/108 A A A 10 B A 32 1.72 A 4 - 
58 23 A - B 174/112 A B B 9 B D 31 1.66 A 14 - 
59 32 B B B 140/90 B A A 4 A - 28 0.88 B - A 
60 21 A - B 154/106 A A A 10 B B 33 1.72 A 9 - 
61 27 A - B 146/108 B A A 5 A - 22 1.58 A A - 
62 29 B B B 148/120 A B A 11 B A 34 1.88 A 7 - 
63 17 A - B 180/110 A A B 3 B D 33 1.68 A 8 - 
64 20 A - B 140/102 B A A 4 A - 31 1.54 A A - 
65 34 B A B 166/114 A A A 12 A - 34 2.10 A 3 A 
66 26 A - B 160/104 A A A 7 A - 32 1.62 A 13 - 
67 28 B B B 144/106 A A B 3 B B 29 1.00 A A - 
68 31 B B B 152/92 B A A 10 A - 34 1.82 A 4 - 
69 24 A - B 142/110 A A A 9 B B 33 1.74 A 4 C 
70 26 A - B 178/108 A A A 6 A - 34 2.18 A 3 - 
71 18 A - B 160/116 A A A 4 A - 31 0.95 B - - 
72 22 A - B 164/110 A A B 8 B D 33 1.70 A 9 - 
73 33 B B B 162/94 A A A 7 B A 30 1.56 A 15 B 
74 20 A - B 172/118 A A A 11 A - 34 2.00 A 11 - 
75 30 B A B 144/120 A B B 4 B D 30 1.25 A 19 - 
76 25 A B B 158/98 B A A 3 A - 29 1.08 A A - 
77 34 B - A 158/106 A A A 4 A - 34 1.68 A 8 - 
  
 
S.No Age Parity 
Past 
History Family 
History 
Blood 
Pressure 
(mm Hg) 
MGSO4 Fundus Induction Latency Days 
Mode of 
Delivery Indication 
Gestational 
Age (Weeks) 
Brith 
Weight 
(KG) 
Alive/ 
Stillbrith 
NICU 
Stay 
(days) 
Maternal 
Complications 
78 22 A - B 170/114 A A B 10 B D 33 2.24 A 7 - 
79 25 A - B 140/96 B A A 8 A - 34 1.85 A 14 - 
80 24 A - B 164/108 A A A 7 A - 32 1.58 A A - 
81 26 A - B 142/92 B A A 9 A - 31 1.67 A 7 - 
82 16 A - B 182/116 A B A 4 B E 32 1.25 A A A 
83 28 B A B 156/104 A A B 3 A - 33 1.74 A 4 - 
84 21 A - B 140/100 A A A 2 A - 28 0.97 B - - 
85 27 A - B 162/102 A A A 4 B B 33 1.72 A 4 - 
86 31 B B B 150/98 A A A 5 A - 33 1.72 A 7 - 
87 23 A - B 156/108 A A B 11 A - 34 2.18 A 2 - 
88 29 B B B 160/104 A A A 3 B A 32 1.66 A 16 - 
89 34 B A B 174/112 A A B 4 A - 31 1.08 A A - 
90 18 A - B 146/106 B A B 12 A - 34 2.00 A 03 - 
91 20 A - B 148/90 B A A 6 A - 33 1.72 A 10 - 
92 22 A - B 150/112 A A A 7 A - 30 1.25 B - - 
93 23 A - A 154/114 A A A 8 A - 31 1.3 B - - 
94 24 B - A 158/102 A A A 8 A - 31 1.75 A 9 - 
95 20 A - B 160/106 A A A 7 A - 31 1.26 B - - 
96 20 A - B 152/124 A B A 6 A - 30 1.24 B - - 
97 24 A - A 168102 A A A 9 A - 31 1.4 B - - 
98 25 A - B 156/108 A A A 10 A - 31 1.6 B - - 
99 27 B B A 160/124 A B A 14 A - 32 1.8 B - - 
100 28 A - B 156/110 A B A 12 A - 32 2 A 8 - 
 
  
 
KEY TO MASTER CHART  
 
 
 
 
 
 
 
PARITY 
A. Primi 
B.  Second gravida 
C. Third gravida 
D. Fouth gravida 
E. Fifth gravida 
PAST HISTORY 
A. Past History Present 
B. No past History 
FAMILY HISTORY 
A. Family History Present 
B. No family history 
MgSO4 
A. MgSO4 given 
B. MgSO4  not given 
FUNDUS 
A. Normal 
B. Grade I Hypertensive 
retinopathy 
C. Grade II Hypertensive  
retinopathy 
INDUCTION 
A. Induced 
B. Not induced 
MODE OF DELIVERY 
A. Vaginal 
B. LSCS 
INDICATION 
A. Past LSCS 
B. Non reassuring CTG 
C. Mal Presentation 
D. Failure to progress / unfavourable 
cervix 
E. Abruption 
NICU STAY 
A. Neonatal death 
MATERNAL COMPLICATIONS 
A. Abruption 
B. HELLP / DIC 
C. Eclampsia 
D. Renal failure 
E. Pulmonary edema 
ALIVE/STILL BIRTH 
A. Alive 
B. Still Birth 
 
